Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Amedisys han disminuido a una tasa media anual de -20.2%, mientras que en la industria Healthcare los beneficios crecieron en un 4.4% anualmente. Los ingresos han ido creciendo a una tasa media de 4.4% al año.

Información clave

-20.2%

Tasa de crecimiento de los beneficios

-20.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	15.7%
Tasa de crecimiento de los ingresos	4.4%
Rentabilidad financiera	-1.9%
Margen neto	-0.9%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Amedisys. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:ADY Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	2,251	-21	780
31 Dec 23	2,236	-10	780
30 Sep 23	2,228	3	793
30 Jun 23	2,229	2	789
31 Mar 23	2,234	112	763
31 Dec 22	2,223	119	754
30 Sep 22	2,220	121	745
30 Jun 22	2,216	140	736
31 Mar 22	2,222	191	723
31 Dec 21	2,214	209	711
30 Sep 21	2,206	220	1,033
30 Jun 21	2,196	247	911
31 Mar 21	2,117	202	785
31 Dec 20	2,072	184	668
30 Sep 20	2,021	166	216
30 Jun 20	1,972	128	214
31 Mar 20	1,980	127	219
31 Dec 19	1,956	127	608
30 Sep 19	1,889	127	207
30 Jun 19	1,812	124	197
31 Mar 19	1,731	123	189
31 Dec 18	1,663	119	185
30 Sep 18	1,626	88	181
30 Jun 18	1,583	71	178
31 Mar 18	1,546	42	178
31 Dec 17	1,511	30	177
30 Sep 17	1,474	43	181
30 Jun 17	1,456	40	187
31 Mar 17	1,438	46	190
31 Dec 16	1,419	37	196
30 Sep 16	1,391	41	198
30 Jun 16	1,358	38	193
31 Mar 16	1,313	38	188
31 Dec 15	1,266	-3	173
30 Sep 15	1,230	-7	158
30 Jun 15	1,204	-7	149
31 Mar 15	1,193	-10	142
31 Dec 14	1,188	13	147
30 Sep 14	1,191	-4	153
30 Jun 14	1,192	-103	161
31 Mar 14	1,203	-109	167
31 Dec 13	1,233	-93	170
30 Sep 13	1,278	-191	176
30 Jun 13	1,340	-90	182

Ingresos de calidad: ADY actualmente no es rentable.

Margen de beneficios creciente: ADY actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ADY no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 13% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ADY en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ADY no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (-7.5%).

Rentabilidad financiera

Alta ROE: ADY tiene una rentabilidad financiera negativa (-1.86%), ya que actualmente no es rentable.

Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.78 in 1Q 2023)

Full year 2023 earnings released: US$0.30 loss per share (vs US$3.65 profit in FY 2022)

Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.79 in 3Q 2022)

First quarter 2023 earnings released: EPS: US$0.78 (vs US$0.97 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.65 (vs US$6.41 in FY 2021)

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Recent updates

First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.78 in 1Q 2023)

Full year 2023 earnings released: US$0.30 loss per share (vs US$3.65 profit in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.79 in 3Q 2022)

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 18%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

First quarter 2023 earnings released: EPS: US$0.78 (vs US$0.97 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.65 (vs US$6.41 in FY 2021)

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Now 21% undervalued after recent price drop

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.79 (vs US$1.38 in 3Q 2021)

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

First quarter 2022 earnings released: EPS: US$0.97 (vs US$1.52 in 1Q 2021)

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought €125k worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Independent Director recently sold €1.8m worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

President & COO recently sold €64k worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold €420k worth of stock

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

New 90-day low: €195

Independent Director recently bought €215k worth of stock

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Revenue misses expectations

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

New 90-day high: €254

New 90-day high: €242

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

New 90-day high: €236

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

New 90-day high: €228

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day high: €214

New 90-day high - €204

New 90-day high - €200

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Desglose de ingresos y gastos
Beta